1887

Journal of General Virology header logo

Volume 68, Issue 6

Synthesis of Cytomegalovirus DNA Is an Antiviral Target Late in Virus Growth Free

Abstract

Summary

The mechanism of action of 9-(l,3-dihydroxypropoxymethyl)guanine (DHPG) and phosphonoformic acid (PFA) but not 5-fluorouridinedeoxyribose (FUdR), provides selective action against cytomegalovirus (CMV)-coded events and this was used to demonstrate that the synthesis of viral DNA was continuous during the extended phase of virus growth. The synthesis of viral DNA was measured by restriction enzyme analysis after exposure to [P]orthophosphate and its interruption by DHPG or PFA resulted in a cessation in the extrusion of infective virus from treated cells. The rate of decline in infectivity appeared to correspond to the failure of cells to maintain the synthesis of late proteins once DNA synthesis was blocked. Thus, regulation of late protein synthesis appeared to be linked to synthesis of viral DNA even at late stages in CMV growth. The synthesis of the polyamines spermidine and spermine, considered obligatory for CMV growth, was unaffected by early or late inhibition of viral DNA and this showed that some virus-induced events were unaffected by the restriction on virus growth by DHPG. This provided evidence that polyamine biosynthesis was a target independent of viral DNA synthesis which may be important in future considerations of combined drug therapies.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): CMV , DHPG and polyamines
© The Journal of General Virology 1987
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-68-6-1563
1987-06-01
2024-05-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/68/6/JV0680061563.html?itemId=/content/journal/jgv/10.1099/0022-1317-68-6-1563&mimeType=html&fmt=ahah

References

  1. Apperley J. F., Marcus R. E., Goldman J. M., Wardle D. G., Gravett P. J., Chanas A. 1985; FoSCamet for cytomegalovirus pneumonitis. Lancet i:1151
     [Google Scholar]
  2. Bach M. C., Bagwell S. P., Knapp N. P., Davis K. M., Hedstrom P. S. 1985; 9-(l,3-DihydroXy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 103:381–382
     [Google Scholar]
  3. Baublis J. V., Whitley R. J., Chien L. T., Alford C. A. 1975; Treatment of cytomegalovirus infection in infants and adults. In Adenine Arabinoside: An Antiviral Agent pp 247–260 Pavan-Langston D., Buchanan R. A., Alford C. A. Edited by New York: Raven Press;
     [Google Scholar]
  4. Cangir A., Sullivan M. P., Sutow W. W., Taylor S. 1967; Cytomegalovirus syndrome in children with acute leukaemia. Treatment with floxuridine. Journal of the American Medical Association 201:612–615
     [Google Scholar]
  5. Cheetham B. F., Bellett A. J. D. 1982; Biochemical investigations of the adenovirus-induced G1 to S phase progression: thymidine kinase, ornithine decarboxylase and inhibitors of polyamine biosynthesis. Journal of Cellular Physiology 110:114–122
     [Google Scholar]
  6. Cheetham B. F., Shaw D. C., Bellett A. J. D. 1982; . Adenovirus type 5 induces progression of quiescent rat cells into S phase without polyamine accumulation Molecular and Cellular Biology 2:1295–1302
     [Google Scholar]
  7. Cheng Y.-C., Ostrander N., Derse D., Chen J.-Y. 1979; Development of antiherpes virus agents on the basis of virus-induced enzymes. In Nucleoside Analogues pp 319–335 Walker R. T., De Clercq E., Eckstein F. Edited by New York: Plenum Press;
     [Google Scholar]
  8. Cheng Y.-C., Huang E.-S., Lin J.-C., Mar E.-C., Pagano J. S., Dutschman G. E., Grill S. P. 1983; Unique spectrum of activity of 9-(l,3-dihydroxy-2-propoxymethyl) guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proceedings of the National Academy of Sciences U.S.A.: 802767–2770
     [Google Scholar]
  9. Clarke J. R., Tyms A. S. 1986; Rapid analysis of polyamines in cell culture by high performance liquid chromatography. Medical Laboratory Sciences 43:258–261
     [Google Scholar]
  10. COLLABORATIVE DHPG TREATMENT STUDY GROUP 1986; Treatment of serious cytomegalovirus infections with 9-(l,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. New England Journal of Medicine 314801–805
     [Google Scholar]
  11. Conchie A. F., Barton B. W., Tobin J. O’H. 1968; Congenital cytomegalovirus infection treated with idoxuridine. British Medical Journal 4:162–169
     [Google Scholar]
  12. Feigin R. D., Shackleford P. G., Devivo D. C., Haymond M. W. 1971; Floxuridine treatment of congenital cytomegalic inclusion disease. Pediatrics 48:318–322
     [Google Scholar]
  13. Felsenstein D., D’Amico D. J., Hirsch M. S., Neumeyer D. A., Cederberg D. M., Demiranda P., Schooley R. T. 1985; Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-l-(hydroxymethyl)ethoxymethyl]guanine. Armais of Internal Medicine 103:377–380
     [Google Scholar]
  14. Fiddian A. P., Brigden D., Yeo J. M., Hickmott E. A. 1984; Acyclovir: an update of the clinical applications of this antiherpes agent. Antiviral Research 4:99–117
     [Google Scholar]
  15. Geballe A. P., Leach F. S., Mocarski E. S. 1986; Regulation of cytomegalovirus late gene expression: genes are controlled by post-transcriptional events. Journal of Virology 57:864–874
     [Google Scholar]
  16. Gehrz R. C., Knorr S. D., Marker S. C., Kalis J. M., Balfour H. H. Jr 1977; Specific cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers. Lancet ii:844–847
     [Google Scholar]
  17. Gibson W. 1983; Protein counterparts of human and simian cytomegaloviruses. Virology 128:391–406
     [Google Scholar]
  18. Gibson W., Irmiere A. 1984; Selection of particles and proteins for use as human cytomegalovirus vaccines. In CMV: Pathogenesis and Prevention of Human Infection (Birth Defects: Original Article Series 20 pp 305–324 Plotkin S. A., Michelson S., Pagano J., Rapp F. Edited by March of Dimes Birth Defects Foundation;
     [Google Scholar]
  19. Gibson W., Vanbreeman R., Fields A., Lafemina R., ARmiere A. 1984; dl-α-Difluoromethylomithine inhibits human cytomegalovirus replication. Journal of Virology 50:45–54
     [Google Scholar]
  20. Goodheart C. R., Filbert J. E., Mcallister R. M. 1963; Human cytomegaloviruses. Effects of 5-fluorodeoxyuridine on viral synthesis and cytopathology. Virology 21:530–532
     [Google Scholar]
  21. Hoffmann P. J., Cheng Y.-C. 1979; DNase induced after infection of KB cells by herpes simplex virus type 1 and type 2. II. Characterization of an associated endonuclease activity. Journal of Virology 32:449–457
     [Google Scholar]
  22. Isom H. C. 1979; Stimulation of ornithine decarboxylase by human cytomegalovirus. Journal of General Virology 42:265–278
     [Google Scholar]
  23. Jordan M. C. 1983; Latent infection and the elusive cytomegalovirus. Reviews of Infectious Diseases 5:205–215
     [Google Scholar]
  24. Mar E.-C., Cheng Y.-C. 1983; Effect of 9-(l,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro . Antimicrobial Agents and Chemotherapy 24:518–521
     [Google Scholar]
  25. Mar E.-C., Chiou J.-F., Cheng Y.-C. 1985; Inhibition of cellular DNA polymerase and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(l,3-dihydroxy-2-propoxymethyl)guanine. Journal of Virology 53:776–780
     [Google Scholar]
  26. Masur H., Lane C., Palestine A. 1986; Effect of 9-(l,3 dihydroxy-2-propoxymethyl)guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. Annals of Internal Medicine 104:41–44
     [Google Scholar]
  27. Meyers J. D., Fleurnoy N., Thomas E. D. 1982; Non-bacterial pneumonitis after allogeneic marrow transplantation: a review of ten years experience. Reviews of Infectious Diseases 6:1119–1132
     [Google Scholar]
  28. Mocarski E. S., Stinski M. F. 1979; Persistence of the cytomegalovirus genome in human cells. Journal of Virology 31:761–775
     [Google Scholar]
  29. Peckham C. S., Chin K. S., Coleman J. C., Hurley R. 1983; Cytomegalovirus infection in pregnancy;preliminary findings from a prospective study. Lancet i:1352–1355
     [Google Scholar]
  30. Pegg A. E., Mccann P. P. 1982; Polyamine metabolism and function. American Journal of Physiology 243: Cell Physiology 12 C212–221
     [Google Scholar]
  31. Plotkin S. A., Stetler H. 1969; Treatment of congenital cytomegalic inclusion disease with antiviral agents. Antimicrobial Agents and Chemotherapy 9:372–379
     [Google Scholar]
  32. Ramirez M. L., Virmani M., Garon C., Rosenthal L. G. 1979; Defective virions of human cytomegalovirus. Virology 96:311–314
     [Google Scholar]
  33. Reynolds D. W., Stagno S., Hosty T. S., Tiller M., Alford C. A. 1973; Maternal cytomegalovirus excretion and perinatal infection. New England Journal of Medicine 289:1–5
     [Google Scholar]
  34. Ringden O., Wilczek H., Lonnquist B., Gahrton G., Wahren B., Lernestedt J.-O. 1985; Foscamet for cytomegalovirus infections. Lancet i:1503–1504
     [Google Scholar]
  35. Salzman N. P. 1960; The rate of formation of vaccinia DNA and vaccinia virus. Virology 10:150–152
     [Google Scholar]
  36. Santi D. V., Mchenry C. S., Summer M. 1974; Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridine. Biochemistry 13:471–481
     [Google Scholar]
  37. Shepp D. H., Dandliker P. S., De Miranda P., Burnette T. C., Cererberg D. M., Kirk L. E., Meyers J. D. 1985; Activity of 9-(2-hydroxy-l-(hydroxymethyl)ethoxymethyl)guanine in the treatment of cytomegalovirus pneumonia. Annals of Internal Medicine 103:368–373
     [Google Scholar]
  38. Smee D. F., Martin I. C., Verheyden J. P. H., Matthew T. R. 1983; Anti-herpes activity of the acyclic nucleoside 9-(l,3-dihdroxy-2-propoxymethyl)guanine. Antimicrobial Agents and Chemotherapy 23:676–682
     [Google Scholar]
  39. Stagno S., Reynolds D. W., Tsiantos A., Fuccillo D. A., Long W., Alford C. A. 1975; Comparative serial virologic and serologic studies of symptomatic and sub-clinical congenitally and natally acquired cytomegalovirus infections. Journal of Infectious Diseases 132:568–577
     [Google Scholar]
  40. Stevens J. G. 1975; Latent herpes simplex virus and the nervous system. Current Topics in Microbiology and Immunology 70:31–50
     [Google Scholar]
  41. Stinski M. F. 1978; Sequence of protein synthesis in cells infected by human cytomegalovirus: early and late virus-induced polypeptides. Journal of Virology 26:686–701
     [Google Scholar]
  42. Stinski M. F., Mocarski E. S., Thomsen D. R. 1979; DNA of human cytomegalovirus: size heterogeneity and defectiveness resulting from serial undiluted passage. Journal of Virology 31:231–239
     [Google Scholar]
  43. Tyms A. S., Williamson J. D. 1980; Polyamine metabolism in MRC-5 cells infected with human cytomegalovirus. Journal of General Virology 48:183–191
     [Google Scholar]
  44. Tyms A. S., Williamson J. D. 1982; Inhibitors of polyamine biosynthesis block human cytomegalovirus replication. Nature; London: 297690–691
     [Google Scholar]
  45. Tyms A. S., Williamson J. D. 1986; Inhibition of viral polyamine biosynthesis. In Inhibition of Polyamine Biosynthesis Mccann P. P., Pegg A. E., Sjoerdsma A. Edited by Orlando: Academic Press; in press
    [Google Scholar]
  46. Tyms A. S., Rawal B. K., Naim H. M., Williamson J. D. 1983; The antiviral effect of inhibitors of polyamine metabolism. Advances in Polyamine Research 4:507–517
     [Google Scholar]
  47. Tyms A. S., Meyers J. D., Davis J. M., Jeffries D. J. 1984a; BWB759U, an analogue of acyclovir, is an effective inhibitor of human cytomegalovirus in vitro . Lancet ii:924–925
     [Google Scholar]
  48. Tyms A. S., Stevens R. J., Mobberley M. A., Ryder T. A., Jeffries D. J. 1984b; Human cytomegalovirus infections in vitro after treatment with Arildone. Journal of General Virology 65:2129–2139
     [Google Scholar]
  49. Wahren B., Oberg B. 1980; Reversible inhibition of a cytomegalovirus replication by phosphono-formate. Intervirology 14:7–15
     [Google Scholar]
  50. Wahren B., Ruder U., Gadler H., Oberg B., Eriksson B. 1985; Activity of the cytomegalovirus genome in the presence of PR analogs. Journal of Virology 56:996–1001
     [Google Scholar]
  51. Weber J. M., Dery C. V., Mirza M. H., Horvath J. 1985; Adenovirus DNA synthesis is coupled to virus assembly. Virology 140:351–359
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-68-6-1563
Loading
Synthesis of Cytomegalovirus DNA Is an Antiviral Target Late in Virus Growth
J. Gen. Virol. 68, 1563 (1987); https://doi.org/10.1099/0022-1317-68-6-1563
/content/journal/jgv/10.1099/0022-1317-68-6-1563
/content/journal/jgv/10.1099/0022-1317-68-6-1563
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error